KROMATID Successfully Completes $8 Million Series C Funding, Breaking Growth Targets KROMATID has successfully closed an $8 million Series C funding round, exceeding their capital goals and positioning the company for accelerated growth.

KROMATID Successfully Completes $8 Million Series C Funding, Breaking Growth Targets #United_States #Boulder #funding #genomic_analysis #KROMATID

KROMATID Partners with Consortium for Cancer Genomics Advancements Using Leading Sequencing Technologies KROMATID announces its essential collaboration in a groundbreaking consortium for cancer genomics, enhancing sequencing standards and resources.

KROMATID Partners with Consortium for Cancer Genomics Advancements Using Leading Sequencing Technologies #USA #Boulder,_Colorado #NIST #Cancer_Genomics #KROMATID

KROMATID Unveils Next-Gen KROMASURE™ PinPoint for Transgene Integration Analysis KROMATID introduces its cutting-edge KROMASURE™ PinPoint, a transformative platform enhancing gene integration analysis with unprecedented precision and high-throughput capabilities.

KROMATID Unveils Next-Gen KROMASURE™ PinPoint for Transgene Integration Analysis #USA #gene_therapy #Boulder #KROMATID #KROMASURE™_PinPoint